KUBio Box for Viral Vectors

November 1, 2019

BioPharm International

Volume 32, Issue 11

GE Healthcare Life Sciences launched the new KUBio box for the production of viral vector-based gene therapies.

GE Healthcare Life Sciences launched the new KUBio box for the production of viral vector-based gene therapies. The device is the most recent addition the company’s KUBio modular bioprocessing portfolio.

Designed to fit into new facilities and retrofitted existing spaces, the new device supports up to 200-L scale manufacturing, comes equipped with a biosafety level 2 (BSL-2) modular bioprocessing environment, and features a FlexFactory single-use biomanufacturing platform specifically for the production of viral vectors.

The design also supports future expansion at different production scales and product technologies.

GE Healthcare Life Sciences
 

 

 

download issueDownload Issue : BioPharm International-11-01-2019